IGMS IGM Biosciences Inc
Price (delayed)
$1.23
Market cap
$73.52M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.24
Enterprise value
$92.05M
Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing
Highlights
The EPS is up by 31% year-on-year and by 10% since the previous quarter
The company's net income rose by 21% YoY and by 11% QoQ
IGMS's revenue is up by 26% year-on-year but it is down by 8% since the previous quarter
IGM Biosciences's gross profit has increased by 26% YoY but it has decreased by 8% QoQ
IGM Biosciences's equity has plunged by 76% YoY and by 39% from the previous quarter
IGM Biosciences's quick ratio has decreased by 39% YoY
Key stats
What are the main financial stats of IGMS
Market
Valuations
Earnings
Shares outstanding
59.78M
Market cap
$73.52M
Enterprise value
$92.05M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.52
Price to sales (P/S)
27.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
34.36
Revenue
$2.68M
Gross profit
$2.68M
Operating income
-$208.58M
Net income
-$195.8M
EBIT
-$195.8M
EBITDA
-$181.39M
Free cash flow
-$158.81M
Per share
Balance sheet
Liquidity
EPS
-$3.24
EPS diluted
-$3.24
Free cash flow per share
-$2.62
Book value per share
$0.81
Revenue per share
$0.04
TBVPS
$4.39
Total assets
$265.71M
Total liabilities
$217.54M
Debt
$45.19M
Equity
$48.17M
Working capital
$155.98M
Debt to equity
0.94
Current ratio
5.14
Quick ratio
4.89
Net debt/EBITDA
-0.1
Margins
Efficiency
Dividend
EBITDA margin
-6,770.7%
Gross margin
100%
Net margin
-7,308.5%
Operating margin
-7,785.7%
Return on assets
-61%
Return on equity
-190.7%
Return on invested capital
-72.5%
Return on capital employed
-85.8%
Return on sales
-7,308.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IGMS stock price
How has the IGM Biosciences stock price performed over time
Intraday
6.96%
1 week
0%
1 month
-9.56%
1 year
-86.54%
YTD
-79.87%
QTD
6.96%
Financial performance
How have IGM Biosciences's revenue and profit performed over time
Revenue
$2.68M
Gross profit
$2.68M
Operating income
-$208.58M
Net income
-$195.8M
Gross margin
100%
Net margin
-7,308.5%
IGMS's operating margin is up by 37% year-on-year and by 3.2% since the previous quarter
IGM Biosciences's net margin has increased by 37% YoY and by 3% from the previous quarter
IGMS's revenue is up by 26% year-on-year but it is down by 8% since the previous quarter
IGM Biosciences's gross profit has increased by 26% YoY but it has decreased by 8% QoQ
Growth
What is IGM Biosciences's growth rate over time
Valuation
What is IGM Biosciences stock price valuation
P/E
N/A
P/B
1.52
P/S
27.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
34.36
The EPS is up by 31% year-on-year and by 10% since the previous quarter
The stock's P/B is 79% below its last 4 quarters average of 6.7 and 74% below its 5-year quarterly average of 5.4
IGM Biosciences's equity has plunged by 76% YoY and by 39% from the previous quarter
IGMS's price to sales (P/S) is 88% less than its last 4 quarters average of 225.0
IGMS's revenue is up by 26% year-on-year but it is down by 8% since the previous quarter
Efficiency
How efficient is IGM Biosciences business performance
IGMS's return on equity has dropped by 85% year-on-year and by 23% since the previous quarter
The return on sales is up by 37% year-on-year and by 2.9% since the previous quarter
The ROA has contracted by 14% YoY
The return on invested capital rose by 8% year-on-year and by 6% since the previous quarter
Dividends
What is IGMS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IGMS.
Financial health
How did IGM Biosciences financials performed over time
The total assets is 22% greater than the total liabilities
IGM Biosciences's quick ratio has decreased by 39% YoY
The total assets has declined by 37% year-on-year and by 13% since the previous quarter
IGM Biosciences's debt is 6% less than its equity
IGM Biosciences's equity has plunged by 76% YoY and by 39% from the previous quarter
IGMS's debt to equity has soared by 62% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.